How to buy Innate Pharma stock (IPHA)

Innate Pharma is a biotechnology business based in the US. Innate Pharma shares (IPHA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.11 – an increase of 2.93% over the previous week. Innate Pharma employs 168 staff and has a trailing 12-month revenue of around $33.8 million.

Our top picks for where to buy Innate Pharma stock

Buy Innate Pharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Innate Pharma stock price (NASDAQ: IPHA)

Use our graph to track the performance of IPHA stocks over time.

Innate Pharma shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$2.11
52-week range	$1.29 - $3.51
50-day moving average more info button	$1.82
200-day moving average more info button	$2.22
Wall St. target price	$7.41
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.44

Is it a good time to buy Innate Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Innate Pharma price performance over time

Historical closes compared with the close of $2.06 from 2024-12-24

1 week (2024-12-20)	0.49%
1 month (2024-11-27)	37.33%
3 months (2024-09-27)	-6.36%
6 months (2024-06-27)	3.52%

1 year (2023-12-27)	-24.54%
2 years (2022-12-27)	-34.39%
3 years (2021-12-27)	5.08
5 years (2019-12-27)	6.5

Innate Pharma financials

Revenue TTM	$33.8 million
Gross profit TTM	$57.7 million
Return on assets TTM	-13.76%
Return on equity TTM	-78.59%
Profit margin	-100.78%
Book value	$0.36
Market Capitalization more info button	$170.5 million

TTM: trailing 12 months

Innate Pharma share dividends

We're not expecting Innate Pharma to pay a dividend over the next 12 months.

Innate Pharma share price volatility

Over the last 12 months, Innate Pharma's shares have ranged in value from as little as $1.29 up to $3.5107. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innate Pharma's is 0.868. This would suggest that Innate Pharma's shares are less volatile than average (for this exchange).

Innate Pharma overview

Innate Pharma S. A. , a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.

Frequently asked questions

null
What percentage of Innate Pharma is owned by institutions?
Currently 0.503% of Innate Pharma shares are held by institutions. How many people work for Innate Pharma?
Latest data suggests 168 work at Innate Pharma. When does the fiscal year end for Innate Pharma?
Innate Pharma's fiscal year ends in December. Where is Innate Pharma based?
Innate Pharma's address is: 117, Avenue de Luminy, Marseille, France, 13009 What is Innate Pharma's ISIN number?
Innate Pharma's international securities identification number is: US45781K2042 What is Innate Pharma's CUSIP number?
Innate Pharma's Committee on Uniform Securities Identification Procedures number is: 45781K204